Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVES: The aim of this study was to analyse the long-term survival outcomes and prognostic factors of patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma. METHODS: Using a multi-institutional database, we performed a retrospective chart review to identify all patients who had undergone complete resection of stage I-III EGFR-mutated lung adenocarcinoma at 11 acute care hospitals between 2009 and 2016 and had received first-line EGFR-TKI treatment for postoperative recurrence. Adverse events, progression-free survival (PFS) and overall survival (OS) were investigated. Survival outcomes were assessed using Kaplan-Meier analysis. Cox proportional hazards models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for PFS and OS. RESULTS: The study sample comprised 154 patients with a median age of 69. The total numbers of events were 101 for PFS and 60 for OS. The median PFS and OS were 26.1 and 55.4 months, respectively. In the multivariable analysis, EGFR ex 21 L858R mutation (HR: 1.71, 95% CI: 1.15-2.55) and shorter disease-free intervals (HR: 0.98, 95% CI: 0.96-0.99) were significantly associated with shorter PFS. Age (HR: 1.03, 95% CI: 1.00-1.07), smoking history (HR: 2.31, 95% CI: 1.35-3.94) and pathological N2 disease at the initial surgery (HR: 2.30, 95% CI: 1.32-4.00) were significantly associated with shorter OS. CONCLUSIONS: First-line EGFR-TKI treatment was generally associated with favourable survival outcomes in patients with postoperative recurrent EGFR-mutated lung adenocarcinoma. EGFR ex 21 L858R mutation may be an important prognostic factor for shorter PFS.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent <i>EGFR</i>-mutated lung adenocarcinoma: a multi-institutional retrospective study
- Date Crossref
- 23/08/2022
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Japanese Red Cross Society Wakayama Medical Center pays non établi dans la noticeÉtablissement de santé
-
Kyoto University Hospital Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
-
Saga University pays non établi dans la noticeUniversité ou école supérieure
-
Kurashiki Central Hospital Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
-
Osaka Red Cross Hospital Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
-
Otsu Red Cross Hospital Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
-
Kitano Hospital Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
-
Kyoto Katsura Hospital Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
-
Kyoto City Hospital Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
-
Nagara Medical Center Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
-
Tenri Hospital Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
-
Hyogo Prefectural Amagasaki General Medical Center Department of Thoracic Surgery pays non établi dans la noticeÉtablissement de santé
Japanese Red Cross Society Wakayama Medical Center, Department of Thoracic Surgery — Kyoto University Hospital et Saga University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.